Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Down 96.9% in August

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 32,056 shares, a decrease of 96.9% from the August 15th total of 1,029,832 shares. Based on an average daily trading volume, of 141,927 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are short sold.

Fresenius SE & Co. Trading Up 0.6%

Shares of OTCMKTS FSNUY traded up $0.08 during trading on Thursday, reaching $13.00. The company had a trading volume of 70,269 shares, compared to its average volume of 150,275. The stock has a market cap of $29.29 billion, a P/E ratio of 16.46 and a beta of 0.62. The company’s fifty day moving average price is $12.92 and its 200-day moving average price is $12.53. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.41. Fresenius SE & Co. has a 12 month low of $10.33 and a 12 month high of $33.93.

Get Fresenius SE & Co. alerts:

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.33% and a net margin of 6.67%. As a group, research analysts expect that Fresenius SE & Co. will post 1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Fresenius SE & Co. has a consensus rating of “Buy”.

View Our Latest Stock Report on FSNUY

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a Germany-based global health care company headquartered in Bad Homburg. The company develops and provides products and services for hospitals, outpatient care, and patients with chronic or complex medical conditions.

Its principal operating businesses are Fresenius Kabi and Fresenius Helios. Fresenius Kabi supplies medicines, clinical nutrition products, infusion and transfusion technologies, and related devices and services. Fresenius Helios operates hospitals and outpatient facilities, primarily in Germany and Spain, providing a broad range of medical and surgical care.

Fresenius traces its origins to a pharmacy established by the Fresenius family in Frankfurt in the 15th century and has evolved into an international health care group serving markets across Europe, North America, Latin America, Asia, and other regions.

See Also

• Five stocks we like better than Fresenius SE & Co.
• AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
• Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
• 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
• Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle

Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.